חובות לטווח קצר של החברה: Fluidigm (LAB)

The market price for Standard BioTools Inc. (LAB), whose operations are based on laboratory diagnostics, as confirmed by the chart on GURU.Markets, is 0.00. Standard BioTools Inc. (LAB) maintains a staff of key scientists and attracts specialized managers. However, global system sales are complicated by trade barriers and logistical disruptions in Asia. Demand for equipment depends on biotechnology investments, although the shift toward personalized medicine provides stability.

Conservative capital demands absolute transparency of the liability structure to assess a business's solvency. This indicator captures the volume of borrowed funds due within a year, evaluating the current debt load. For Standard BioTools Inc. (LAB), such funds support expansion in the mass cytometry segment, where high B2B customer loyalty guarantees a stable cash flow. Analyzing financial liabilities with a maturity of up to 12 months allows for liquidity tracking between SEC reports. An upward trend in this curve signals an intensification of asset turnover alongside an increase in credit risks.